ADP-ribosylation factor 6 (ARF6) is a small GTP-binding protein belonging to the ARF family, which regulates membrane trafficking, cytoskeletal reorganization, and cellular signaling. As a key regulator of endocytic and exocytic pathways, ARF6 controls the recycling of plasma membrane components, cell adhesion, and migration. Antibodies targeting ARF6 are essential tools for studying its spatial-temporal dynamics, activation states (GTP- or GDP-bound), and interactions with effector proteins like JIP3. PLD, or GGA3 in diverse cellular processes.
ARF6 antibodies are widely used in techniques such as Western blotting, immunoprecipitation, and immunofluorescence to detect its expression, subcellular localization (plasma membrane, endosomes, or tubular vesicles), and activity-dependent redistribution. These antibodies help elucidate ARF6's roles in physiological contexts (e.g., neurite outgrowth, immune response) and pathological conditions, including cancer metastasis, viral infection, and neurological disorders. Commercial ARF6 antibodies are often raised against specific epitopes, such as the N-terminal region (residues 2-175) or C-terminal domains, with validation in knockout models to ensure specificity. Recent studies using ARF6 antibodies have highlighted its involvement in tumor invasion, exosome secretion, and β-amyloid production in Alzheimer’s disease, making it a potential therapeutic target. Researchers prioritize antibodies recognizing both inactive and active conformations to dissect ARF6-mediated molecular mechanisms.